NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA aims to identify an optimal, well-tolerated dosing regimen and will serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. This timeline underscores the company's commitment to advancing a novel therapeutic against a high-consequence pathogen.
The significance of this announcement lies in the potential of NV-387 to address critical gaps in Ebola treatment. Unlike injectable therapies that require cold-chain storage and trained personnel, NV-387 is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. This design could enable rapid deployment in resource-limited settings, where outbreaks often occur and where healthcare infrastructure is fragile. If successful, NV-387 could become a key tool in outbreak response, reducing logistical barriers and improving patient access. The company said NV-387 is designed to attack the virus and reduce viral load, and characterized it as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses. There is a rationale for potential activity against Bundibugyo and other Ebola viruses, which could simplify treatment across different strains.
For investors, the update signals progress in a high-risk, high-reward area of antiviral development. NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy, and its lead drug candidate NV-387 is also being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company's broader pipeline includes NV-HHV-1 for Shingles and drugs against oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Phase II Ebola trial, if successful, could validate the nanoviricide platform and open doors for additional indications.
However, the company notes that drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any candidates will show sufficient effectiveness and safety for human clinical development. The path to regulatory approval remains uncertain, and the Phase IIA results will be closely watched as a key inflection point.
To view the full press release, visit https://ibn.fm/zjg8X. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. NanoViricides' website is www.nanoviricides.com. This update was distributed by BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. For more information, visit https://www.BioMedWire.com.
